Haemonetics Corporation (NYSE:HAE) is one of the 12 best Medical Devices stocks to invest in according to Hedge Funds. Analyst Michael Petusky from Barrington raised his price target on HAE to $93, indicating a 41% upside, following the acquisition of Vivasure Medical. Mizuho Securities also reaffirmed an Outperform rating on HAE with a price target of $90, anticipating a 36% upside potential.

The recent acquisition of Vivasure Medical by Haemonetics Corporation (NYSE:HAE) has garnered positive reactions from analysts, with Mizuho Securities foreseeing further valuation expansion in the medical devices and diagnostics space. The company specializes in hospital technology solutions, plasma, and blood management, offering services that improve patient outcomes, reduce healthcare costs, and enhance blood product quality.

Despite the potential of Haemonetics Corporation (NYSE:HAE) as an investment, some believe that certain AI stocks offer greater upside potential with less downside risk. For those seeking an undervalued AI stock that could benefit from Trump-era tariffs and the onshoring trend, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Haemonetics (HAE) Sparks Confidence Following Vivasure Acquisition